Publications

Sort by: Date | Author | Title

Gane, E. J., Pianko, S., Roberts, S. K., Thompson, A. J., Zeuzem, S., Zuckerman, E., Ben-Ari, Z., Foster, G. R., Agarwal, K., Laursen, A. L., Gerstoft, J., Gao, W., Huang, H.-C., Fitzgerald, B., Fernsler, D., Li, J. J., Grandhi, A., Liu, H., Su, F.-H. ... Esteban, R. (2017). Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials. The Lancet Gastroenterology and Hepatology, 2(11), 805-813. https://doi.org/10.1016/S2468-1253(17)30159-0
Larsen, C. S. (2017). Sekundære immundefekter. In C. K. Holm (Ed.), Immunologi (1 ed., Vol. 1). FADL's Forlag.
Vibholm, L., Schleimann, M. H., Højen, J. F., Benfield, T., Offersen, R., Rasmussen, K., Olesen, R., Dige, A., Agnholt, J., Grau, J., Buzon, M. J., Wittig, B., Lichterfeld, M., Petersen, A. M., Deng, X., Abdel-Mohsen, M., Pillai, S. K., Rutsaert, S., Trypsteen, W. ... Søgaard, O. S. (2017). Short-course TLR9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals with HIV infection. Clinical Infectious Diseases, 64(12), 1686-1695. https://doi.org/10.1093/cid/cix201
Dalgard, O., Weiland, O., Noraberg, G., Karlsen, L., Heggelund, L., Färkkilâ, M., Balslev, U., Belard, E., Øvrehus, A., Skalshøi Kjær, M., Krarup, H., Thorup Røge, B., Hallager, S., Madsen, L. G., Lund Laursen, A., Lagging, M. & Weis, N. (2017). Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study. PLoS One, 12(7), e0179764. Article e0179764. https://doi.org/10.1371/journal.pone.0179764